Abstract:OBJECTIVE: To evaluate the safety and immunogenicity of recombinant glycoprotein (rgp) 120, a candidate vaccine for the human immunodeficiency virus (HIV), formulated with a novel adjuvant, MF59, with or without a biological response modifier, MTP-PE.DESIGN: Multicenter, double-blind, randomized trial.SETTING: University medical centers.PARTICIPANTS: 49 healthy, HIV-seronegative volunteers 18 to 60 years of age who were at low risk for HIV type 1 (HIV-1) infection.INTERVENTIONS: In part A of the study, 32 participants were randomly assigned to receive either 15 micrograms of rgp 120 in MF59, 15 micrograms of rgp 120 in MF59 plus 50 micrograms of MTP-PE, 50 micrograms of rgp 120 in MF59, or 50 micrograms of rgp 120 in MF59 plus 50 micrograms of MTP-PE. Participants were vaccinated at 0, 1, 6, and 12 to 18 months. In part B, 17 participants were randomly assigned to receive five monthly injections of either 50 micrograms of rgp 120 in MF59 or MF59 alone followed by a booster injection at 12 to 18 months.MAIN OUTCOME MEASURES: Local and systemic reactions; laboratory measures of hepatic, renal, immunologic, and bone marrow toxicity; and HIV-specific serologic and cell-mediated immune responses.RESULTS: 13 patients in part A received 50-micrograms doses of rgp 120; type-specific neutralizing antibody responses against the SF-2 strain of HIV-1 (HIV-1/SF-2) were induced in all 13. Nine of the 13 had crossreactive neutralizing activity against the MN strain of HIV-1 (HIV-1/MN), and 2 had crossreactive neutralizing activity against the IIIB strain of HIV-1 (HIV-1/IIIB). Twelve patients had typespecific fusion inhibition activity; only 1 had crossreactive fusion inhibition activity against HIV-1/MN. The monthly vaccination schedule used in part B resulted in decreased antibody titers, indicating that a rest period in the schedule is necessary for maximal immunogenicity. Lymphoproliferative responses against gp120 were induced in all vaccine recipients. The stimulation index to gp120 was persistently greater than 15 for 6 months after the last booster vaccination was given. CD8+ cytotoxic T-lymphocyte activity was detected in 1 of the 11 participants tested. Vaccine that contained MTP-PE caused a greater number of moderate or severe local and systemic reactions (of 16 participants, 4 had local reactions and 13 had systemic reactions) than did vaccine formulated with MF59 alone (of 16 participants, 7 had local reactions [P < 0.01] and 0 had systemic reactions [P < 0.001]).CONCLUSIONS: The SF-2 rgp120 vaccine is safe and immunogenic. Three vaccinations with rgp120 in MF59 can induce type-specific and crossreactive neutralizing antibody against B-subtype laboratory strains of HIV-1. Human immunodeficiency virus-specific lymphoproliferative responses were induced in all vaccinated participants, and CD8+ cytotoxic T-lymphocyte activity was shown in one participant. A trend toward the augmentation of lymphoproliferative and humoral responses by MTP-PE was seen in the participants receiving 15 micrograms of rgp120. However, MTP-PE caused a statistically significant increase in the incidence of local and systemic side effects, which was felt to outweigh the small increase in immunogenicity provided by this biological response modifier in an otherwise well-tolerated vaccine.

GP120-specific exosome-targeted T cell-based vaccine capable of stimulating DC- and CD4+ T-independent CTL responses

Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.

Transgenic 4-1Bbl-engineered Vaccine Stimulates Potent Gag-specific Therapeutic and Long-Term Immunity Via Increased Priming of CD44+CD62Lhigh IL-7R+ CTLs with Up- and Downregulation of Anti- and Pro-Apoptosis Genes

HIV-1 Gag-specific exosome-targeted T cell-based vaccine stimulates effector CTL responses leading to therapeutic and long-term immunity against Gag/HLA-A2-expressing B16 melanoma in transgenic HLA-A2 mice

Novel Exosome-Targeted T-Cell-Based Vaccine Counteracts T-Cell Anergy and Converts Ctl Exhaustion in Chronic Infection Via Cd40l Signaling Through the Mtorc1 Pathway

Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.

The Tat Protein Enhances CTL Responses and Therapeutic Immunity of Gag-Specific Exosome-Targeted T Cell-Based Gag/Tat-Texo Vaccine in Transgenic HLA-A2 Mice

Novel Exosome-Targeted Cd4(+) T Cell Vaccine Counteracting Cd4(+)25(+) Regulatory T Cell-Mediated Immune Suppression and Stimulating Efficient Central Memory Cd8(+) Ctl Responses

In vivo anti-tumor effect of tumor cell-derived exosomes combined with BCG

Expression and Identification of Immunological Activities of the HIV‐gp120N‐Human Interferon Gamma Fusion Protein

Safety and Immunogenicity of a Candidate HIV-1 Vaccine in Healthy Adults: Recombinant Glycoprotein (rgp) 120: A Randomized, Double-Blind Trial

Generation and Characterization of a Bivalent HIV-1 Subtype C Gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa.

Exosomal Pmhc-I Complex Targets T Cell-Based Vaccine to Directly Stimulate CTL Responses Leading to Antitumor Immunity in Transgenic FVBneuN and HLA-A2/HER2 Mice and Eradicating Trastuzumab-Resistant Tumor in Athymic Nude Mice

[Experimental Study on Immune Responses Induced in Mice by Gp120 Gene Vaccine of Chinese HIV-1 Strain].

A Novel T Cell-Based Vaccine Capable of Stimulating Long-Term Functional CTL Memory Against B16 Melanoma Via CD40L Signaling

Protective cellular immunity generated by cross-presenting recombinant overlapping peptide proteins

Exploration of a Sequential Gp140-Gp145 Immunization Regimen with Heterologous Envs to Induce a Protective Cross-Reactive HIV Neutralizing Antibody Response In Non-human Primates

Intra- and Extracellular Immunization Against HIV-1 Infection with Lymphocytes Transduced with an AAV Vector Expressing a Human Anti-gp120 Antibody

Dendritic Cell-Derived Exosomes Stimulate Stronger Cd8(+) Ctl Responses and Antitumor Immunity Than Tumor Cell-Derived Exosomes

A Novel HER-2-specific Exosome-Targeted T Cell-Based Vaccine: Immunotherapy of Established Lung Metastasis in Transgenic HLA-A2/HER-2 Mice (155.37)

The role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccination.